Salmonella enterica serovar typhimurium vaccine strains expressing a nontoxic shiga-like toxin 2 derivative induce partial protective immunity to the toxin expressed by enterohemorrhagic escherichia coli

Clinical and Vaccine Immunology

Volumn 17, Issue 4, 2010, Pages 529-536

  Rojas, Robert L G ^a   Gomes, Priscila A D P ^a   Bentancor, Leticia V ^b   Sbrogio Almeida, Maria E ^c   Costa, Sérgio O P ^a   Massis, Liliana M ^a   Ferreira, Rita C C ^a   Palermo, Marina S ^b   Ferreira, Luís C S ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b ACADEMIA NACIONAL DE MEDICINA   (Argentina)

^c INSTITUTO BUTANTAN   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; CREATININE; FLAGELLIN; IMMUNOGLOBULIN G; NITROGEN; STX2 B SUBUNIT; STX2DELTAAB PROTEIN; TOXIN ANTIBODY; UNCLASSIFIED DRUG; UREA; VEROTOXIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL FLAGELLUM; BACTERIAL IMMUNITY; BACTERIAL STRAIN; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENTEROHEMORRHAGIC ESCHERICHIA COLI; EXTRACELLULAR SPACE; FEMALE; HEMOLYTIC UREMIC SYNDROME; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; INTESTINE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; SALMONELLA TYPHIMURIUM; SEROTYPE; SINGLE DRUG DOSE; UREA NITROGEN BLOOD LEVEL;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, NEUTRALIZING; ANTITOXINS; CERCOPITHECUS AETHIOPS; CREATININE; ENTEROHEMORRHAGIC ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI VACCINES; GENETIC VECTORS; IMMUNIZATION, SECONDARY; MICE; MICE, INBRED BALB C; SALMONELLA TYPHIMURIUM; SHIGA TOXIN 2; UREA; VACCINES, ATTENUATED; VERO CELLS;

EID: 77950684509     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00495-09     Document Type: Article

References (58)

1. Acheson, D. W., M. M. Levine, J. B. Kaper, and G. T. Keusch. 1996. Protective immunity to Shiga-like toxin I following oral immunization with Shiga-like toxin I B subunit-producing Vibrio cholerae CVD 103-HgR. Infect. Immun. 64:355-357.
2. Akira, S., S. Uematsu, and O. Takeuchi. 2006. Pathogen recognition and innate immunity. Cell 124:783-801.
3. Babiuk, S., D. J. Asper, D. Rogan, G. K. Mutwiri, and A. A. Potter. 2008. Subcutaneous and intranasal immunization with type III secreted proteins can prevent colonization and shedding of Escherichia coli in mice. Microb. Pathog. 45:7-11.
4. Bargieri, D. Y., D. S. Rosa, C. J. M. Braga, B. O. Carvalho, F. T. Costa, N. M. Spíndola, A. J. Vaz, I. S. Soares, L. C. S. Ferreira, and M. M. Rodrigues. 2008. New malaria vaccine candidates based on the Plasmodium vivax Mero-zoite Surface Protein-1 and the TLR-5 agonist Salmonella Typhimurium FliC flagellin. Vaccine 26:6132-6142.
5. Bentancor, L. V., M. Bilen, R. J. Fernández Brando, M. V. Ramos, L. C. S. Ferreira, P. D. Ghiringhelli, and M. S. Palermo. 2009. DNA vaccine encoding the enterohemorrhagic Escherichia coli (EHEC) Shiga-like toxin 2 (Stx2) A2 and B subunits confers protective immunity to Stx challenge in the murine model. Clin. Vaccine Immunol. 16:712-718.
6. Bielaszewska, M., I. Clarke, M. A. Karmali, and M. Petric. 1997. Localization of intravenously administered verocytotoxins (Shiga-like toxins) 1 and 2 in rabbits immunized with homologous and heterologous toxoids and toxin subunits. Infect. Immun. 65:2509-2516.
7. Bitzan, M. 2009. Treatment options for HUS secondary to Escherichia coli O157:H7. Kidney Int. Suppl. 112:S62-S66.
8. Braga, C. J. M., G. M. G. Rittner, J. E. M. Henao, A. F. Teixeira, L. M. Massis, M. E. Sbrogio-Almeida, C. P. Taborda, L. R. Travassos, and L. C. S. Ferreira. 2009. Paracoccidioides brasiliensis vaccine formulations based on the gp43-derived P10 sequence and the Salmonella enterica FliC flagellin. Infect. Immun. 77:1700-1707.
9. Brando, R. J. F., E. Miliwebsky, L. V. Bentancor, N. Deza, A. Baschkier, M. V. Ramos, G. C. Fernández, R. Meiss, M. Rivas, and M. S. Palermo. 2008. Renal damage and death in weaned mice after oral infection with Shiga toxin 2-producing Escherichia coli strains. Clin. Exp. Immunol. 153:297-306.
10. Butterton, J. R., E. T. Ryan, D. W. Acheson, and S. B. Calderwood. 1997. Coexpression of the B subunit of Shiga toxin 1 and EaeA from enterohem-orrhagic Escherichia coli in Vibrio cholerae. Infect. Immun. 65:2127-2135.
11. Byun, Y., M. Omura, K. Fujihashi, S. Yamamoto, J. R. McGhee, S. Udaka, H. Kiyono, Y. Takeda, T. Kosaka, and Y. Yuki. 2001. Nasal immunization with E. coli verotoxin 1 (VT1)-B subunit and a nontoxic mutant of cholera toxin elicits serum neutralizing antibodies. Vaccine 19:2061-2070.
12. Capozzo, A. V. E., V. P. Creydt, G. Dran, G. Fernández, S. Gómez, L. V. Bentancor, C. Rubel, C. Ibarra, M. Isturiz, and M. S. Palermo. 2003. Development of DNA vaccines against hemolytic-uremic syndrome in a murine model. Infect. Immun. 71:3971-3978.
13. Caprioli, A., S. Morabito, H. Brug̀ere, and E. Oswald. 2005. Enterohaem-orrhagic Escherichia coli: emerging issues on virulence and modes of transmission. Vet. Res. 36:289-311.
14. Friedrich, A. W., M. Bielaszewska, W. L. Zhang, M. Pulz, T. Kuczius, A. Ammon, and H. Karch. 2002. Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms. J. Infect. Dis. 185:74-84.
15. Galen, J. E., M. F. Pasetti, S. Tennant, P. Ruiz-Olvera, M. B. Sztein, and M. M. Levine. 2009. Salmonella enterica serovar Typhi live vector vaccines finally come of age. Immunol. Cell Biol. 87:400-412.
16. Garmory, H. S., S. E. Leary, K. F. Griffin, E. D. Williamson, K. A. Brown, and R. W. Titball. 2003. The use of live attenuated bacteria as a delivery system for heterologous antigens. J. Drug Target. 11:471-479.
17. Gomes, P. A. D. P., L. V. Bentancor, J. D. Paccez, M. E. Sbrogio-Almeida, M. S. Palermo, R. C. C. Ferreira, and L. C. S. Ferreira. 2009. Antibody responses elicited in mice immunized with Bacillus subtilis vaccine strains expressing Stx2B subunit of enterohaemorrhagic Escherichia coli O157:H7. Braz. J. Microbiol. 40:333-338.
18. Griffin, P. M., and R. V. Tauxe. 1991. The epidemiology of infections caused by Escherichia coli O157:H7, other enterohemorrhagic E. coli, and the associated hemolytic uremic syndrome. Epidemiol. Rev. 13:60-98.
19. Harari, I., and R. Arnon. 1990. Carboxy-terminal peptides from the B sub-unit of Shiga toxin induce a local and parenteral protective effect. Mol. Immunol. 27:613-621.
20. Harari, I., A. Donohue-Rolfe, G. Keusch, and R. Arnon. 1988. Synthetic peptides of Shiga toxin B subunit induce antibodies which neutralize its biological activity. Infect. Immun. 56:1618-1624.
21. Hoiseth, S. K., and B. A. Stocker. 1981. Aromatic-dependent Salmonella Typhimurium are non-virulent and effective as live vaccines. Nature 291: 238-239.
22. Honko, A. N., N. Sriranganathan, C. J. Lees, and S. B. Mizel. 2006. Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis. Infect. Immun. 74:1113-1120.
23. Huleatt, J. W., A. R. Jacobs, J. Tang, P. Desai, E. B. Kopp, Y. Huang, L. Song, V. Nakaar, and T. J. Powell. 2007. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 25:763-765.
24. Imai, Y., R. Nagai, Y. Ono, T. Ishikawa, H. Nakagami, T. Tanikawa, and K. Kurohane. 2004. Production of secretory immunoglobulin A against Shiga toxin-binding subunits in mice by mucosal immunization. Infect. Immun. 72:889-895.
25. Ishikawa, S., K. Kawahara, Y. Kagami, Y. Isshiki, A. Kaneko, H. Matsui, N. Okada, and H. Danbara. 2003. Protection against Shiga toxin 1 challenge by immunization of mice with purified mutant Shiga toxin 1. Infect. Immun. 71:3235-3239.
26. Janeway, C. A., Jr., and R. Medzhitov. 2002. Innate immune recognition. Annu. Rev. Immunol. 20:197-216.
27. Karmali, M. A. 2004. Infection by Shiga toxin-producing Escherichia coli: an overview. Mol. Biotechnol. 26:117-122.
28. Konadu, E., A. Donohue-Rolfe, S. B. Calderwood, V. Pozsgay, J. Shiloach, J. B. Robbins, and S. C. Szu. 1999. Syntheses and immunologic properties of Escherichia coli O157 O-specific polysaccharide and Shiga toxin 1 B subunit conjugates in mice. Infect. Immun. 67:6191-6193.
29. Marcato, P., G. Mulvey, R. J. Read, K. Vander Helm, P. N. Nation, and G. D. Armstrong. 2001. Immunoprophylactic potential of cloned Shiga toxin 2 B subunit. J. Infect. Dis. 183:435-443.
30. Marcato, P., T. P. Griener, G. L. Mulvey, and G. D. Armstrong. 2005. Recombinant Shiga toxin B-subunit-keyhole limpet hemocyanin conjugate vaccine protects mice from shigatoxemia. Infect. Immun. 73:6523-6529.
31. Massis, L. M., C. J. Braga, M. E. Sbrogio-Almeida, C. Lauand, S. M. Newton, P. E. Klebba, and L. C. S. Ferreira. 2008. Anti-flagellin antibody responses elicited in mice orally immunized with attenuated Salmonella enterica serovar Typhimurium vaccine strains. Mem. Inst. Oswaldo Cruz 103:606-610.
32. Mizel, S. B., and J. A. Snipes. 2002. Gram-negative flagellin-induced self-tolerance is associated with a block in interleukin-1 receptor-associated kinase release from toll-like receptor 5. J. Biol. Chem. 277:22414-22420.
33. Nataro, J. P., and J. B. Kaper. 1998. Diarrheagenic Escherichia coli. Clin. Microbiol. Rev. 11:142-201.
34. Nisole, S., B. Krust, and A. G. Hovanessian. 2002. Anchorage of HIV on permissive cells leads to coaggregation of viral particles with surface nucleo-lin at membrane raft microdomains. Exp. Cell Res. 276:155-173.
35. Oxer, M. D., C. M. Bentley, J. G. Doyle, T. C. Peakman, I. G. Charles, and A. J. Makoff. 1991. High levels of heterologous expression in E. coli using the anaerobically-activated nirB promoter. Nucleic Acids Res. 19:2889-2892.
36. Pino, O., M. Martin, and S. M. Michalek. 2005. Cellular mechanisms of the adjuvant activity of the flagellin component FljB of Salmonella enterica serovar Typhimurium to potentiate mucosal and systemic responses. Infect. Immun. 73:6763-6770.
37. Potter, A. A., S. Klashinsky, Y. Li, E. Frey, H. Townsend, D. Rogan, G. Erickson, S. Hinkley, T. Klopfenstein, R. A. Moxley, D. R. Smith, and B. B. Finlay. 2004. Decreased shedding of Escherichia coli O157:H7 by cattle following vaccination with type III secreted proteins. Vaccine 22:362-369.
38. Rivas, M., E. Miliwebsky, I. Chinen, C. D. Roldán, L. Balbi, B. Garcia, G. Fiorilli, S. Sosa-Estani, J. Kincaid, J. Rangel, and P. M. Griffin. 2006. Characterization and epidemiologic subtyping of Shiga-toxin-producing Escherichia coli strains isolated from hemolytic uremic syndrome and diarrhea cases in Argentina. Foodborne Pathog. Dis. 3:88-96.
39. Robinson, C. M., J. F. Sinclair, M. J. Smith, and A. D. O'Brien. 2006. Shiga toxin of enterohemorrhagic Escherichia coli type O157:H7 promotes intestinal colonization. Proc. Natl. Acad. Sci. U. S. A. 103:9667-9672.
40. Sanders, C. J., Y. Yu, D. A. Moore III, I. R. Williams, and A. T. Gewirtz. 2006. Humoral immune response to flagellin requires T cells and activation of innate immunity. J. Immunol. 177:2810-2818.
41. Sauter, K. A. D., A. R. Melton-Celsa, K. Larkin, M. L. Troxell, A. D. O'Brien, and B. E. Magun. 2008. Mouse model of hemolytic-uremic syndrome caused by endotoxin-free Shiga toxin 2 (Stx2) and protection from lethal outcome by anti-Stx2 antibody. Infect. Immun. 76:4469-4478.
42. Sbrogio-Almeida, M. E., and L. C. S. Ferreira. 2001. Flagellin expressed by live Salmonella vaccine strains induces distinct antibody responses following delivery via systemic or mucosal immunization routes. FEMS Immunol. Med. Microbiol. 30:203-208.
43. Sbrogio-Almeida, M. E., T. Mosca, L. M. Massis, I. A. Abrahamsohn, and L. C. S. Ferreira. 2004. Host and bacterial factors affecting induction of immune responses to flagellin expressed by attenuated Salmonella vaccine strains. Infect. Immun. 72:2546-2555.
44. Sheoran, A. S., S. Chapman-Bonofiglio, B. R. Harvey, J. Mukherjee, G. Georgiou, A. Donohue-Rolfe, and S. Tzipori. 2005. Human antibody against Shiga toxin 2 administered to piglets after the onset of diarrhea due to Escherichia coli O157:H7 prevents fatal systemic complications. Infect. Im-mun. 73:4607-4613.
45. Siegler, R., and R. Oakes. 2005. Hemolytic uremic syndrome: pathogenesis, treatment, and outcome. Curr. Opin. Pediatr. 17:200-204.
46. Smith, K. D., E. Andersen-Nissen, F. Hayashi, K. Strobe, M. A. Bergman, S. L. R. Barrett, B. T. Cookson, and A. Aderem. 2003. Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility. Nat. Immunol. 4:1247-1253.
47. Smith, J. J., L. D. Teel, H. M. Carvalho, A. R. Melton-Celsa, and A. D. O'Brien. 2006. Development of a hybrid Shiga holotoxoid vaccine to elicit heterologous protection against Shiga toxins types 1 and 2. Vaccine 24:4122-4129.
48. Stocker, B. A. 2000. Aromatic-dependent Salmonella as anti-bacterial vaccines and as presenters of heterologous antigens or of DNA encoding them. J. Biotechnol. 83:45-50.
49. Su, G. F., H. N. Brahmbhatt, J. Wehland, M. Rohde, and K. N. Timmis. 1992. Construction of stable LamB-Shiga toxin B subunit hybrids: analysis of expression in Salmonella typhimurium aroA strains and stimulation of B-subunit-specific mucosal and serum antibody responses. Infect. Immun. 60: 3345-3359.
50. Tarr, P. I., C. A. Gordon, and W. L. Chandler. 2005. Shiga toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 365:1073-1086.
51. Tesh, V. L., and A. D. O'Brien. 1991. The pathogenic mechanisms of Shiga toxin and the Shiga-like toxins. Mol. Microbiol. 5:1817-1822.
52. Trachtman, H., A. Cnaan, E. Christen, K. Gibbs, S. Zhao, D. W. Acheson, R. Weiss, F. J. Kaskel, A. Spitzer, and G. H. Hirschman. 2003. Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial. JAMA 290:1337-1344.
53. Tsuji, T., T. Shimizu, K. Sasaki, H. Shimizu, K. Tsukamoto, H. Arimitsu, S. Ochi, S. Sugiyama, K. Tanaguchi, P. Neri, and H. Mori. 2008. Protection of mice from Shiga toxin-2 toxemia by mucosal vaccine of Shiga toxin 2B-His with Escherichia coli enterotoxin. Vaccine 26:469-476.
54. Vilte, D. A., M. Larzábal, A. A. Cataldi, and E. C. Mercado. 2008. Bovine colostrum contains immunoglobulin G antibodies against intimin, EspA, and EspB and inhibits hemolytic activity mediated by the type three secretion system of attaching and effacing Escherichia coli. Clin. Vaccine Immunol. 15:1208-1213.
55. Wen, S. X., L. D. Teel, N. A. Judge, and A. D. O'Brien. 2006. Genetic toxoids of Shiga toxin types 1 and 2 protect mice against homologous but not heterologous toxin challenge. Vaccine 24:1142-1148.
56. Winter, S. E., P. Thiennimitr, S. P. Nuccio, T. Haneda, M. G. Winter, R. P. Wilson, J. M. Russell, T. Henry, Q. T. Tran, S. D. Lawhon, G. Gomez, C. L. Bevins, H. Rüssmann, D. M. Monack, L. G. Adams, and A. J. Bäumler. 2009. Contribution of flagellin pattern recognition to intestinal inflammation during Salmonella enterica serotype Typhimurium infection. Infect. Immun. 77:1904-1916.
57. Yoshioka, A., R. Okamoto, S. Oshima, J. Akiyama, K. Tsuchiya, T. Naka-mura, T. Kanai, and M. Watanabe. 2008. Flagellin stimulation suppresses IL-7 secretion of intestinal epithelial cells. Cytokine 44:57-64.
58. Zhu, C., J. Yu, Z. Yang, K. Davis, H. Rios, I. B. Wang, G. Glenn, and E. C. Boedeker. 2008. Protection against Shiga toxin-producing Escherichia coli infection by transcutaneous immunization with Shiga toxin subunit B. Clin. Vaccine Immunol. 15:359-366.